Videos
Consensus Guidelines for Spasticity Assessment and Management: Monica Verduzco-Gutierrez, MD
May 24th 2024The professor and chair of rehabilitation medicine at UT Health San Antonio talked about the newly published guidelines for the assessment and management of spasticity in patients with neurological conditions. [WATCH TIME: 5 minutes]
Innovative Therapies to Address Unmet Needs in Acute Ischemic Stroke: Shahid Nimjee, MD, PhD
May 23rd 2024The vascular neurosurgeon and professor of neurological surgery at The Ohio State University Wexner Medical Center spoke about advancements in stroke treatment, including endovascular thrombectomy and new drug therapies, that aim to address unmet need in patients. [WATCH TIME: 5 minutes]
Utilization of Neuroimaging in Alzheimer’s Disease
May 20th 2024Key opinion leaders emphasize the importance of neuroimaging in Alzheimer's disease, as it can rule out different diseases and diagnose microbleeds, while also discussing which biomarkers, histopathological features, and imaging characteristics are associated with different stages of the disease, exploring whether these tools can provide insights into the true onset of Alzheimer's disease.
Contribution of Multiple Pathways to the Development of Alzheimer’s Disease
May 20th 2024Sharon Cohen, MD, and Marwan Sabbagh, MD, discuss the current understanding of tau as a marker of neuronal injury and its role in the pathophysiology of Alzheimer's disease, particularly focusing on the significance of phosphorylated tau and neurofibrillary tangles in the disease process.
Future Directions and Takeaways Regarding Anti-CD20 Therapies in MS
May 20th 2024Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.
Efficacy of Switching From to Inebilizumab in Rituximab in NMOSD: Michael Levy, MD, PhD
Published: May 16th 2024 | Updated: May 20th 2024The associate professor of neurology at Harvard Medical School talked about findings from a recent case series of patients with NMOSD initially on rituximab who then switched to inebilizumab. [WATCH TIME: 4 minutes]
The Promising Future of Gene Therapy in Treating Neurological Diseases: Michael Kaplitt, MD, PhD
May 15th 2024The professor of neurological surgery at Weill Cornell medicine talked about how gene therapy may offer a more direct and efficient pathway to develop treatments for neurological diseases like Parkinson disease. [WATCH TIME: 6 minutes]
Insights Into Nasal Pathways for Brain Protein Sampling and Treatment Delivery: Mony de Leon, EdD
Published: May 15th 2024 | Updated: May 15th 2024The director of the Brain Health Imaging Institute in the department of radiology at Weill Cornell Medicine talked about exploring nasal pathways as an alternative for brain protein sampling and drug delivery. [WATCH TIME: 4 minutes]
Open-Label Data vs Real-World Data for Anti-CD20 Therapies in Multiple Sclerosis
May 14th 2024Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the utility of real-world data, particularly when it comes to understanding subtle differences between agents from both a safety and efficacy perspective.
Downstream Impacts of Undiagnosed Lennox-Gastaut Syndrome: Scott Perry, MD
May 14th 2024The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center detailed some of consequences of undiagnosed or misdiagnosed LGS, and how it may impact long-term care for eligible patients. [WATCH TIME: 4 minutes]
Amyloid Cascade Hypothesis of Alzheimer’s Disease
May 13th 2024Panelists delve into the amyloid cascade hypothesis of Alzheimer's disease and the ongoing debate surrounding it, discussing the presence and potential roles of Aβ monomers, oligomers, protofibrils, and amyloid plaques in patients with Alzheimer's disease.
Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease
May 13th 2024The panel provides an overview of amyloid precursor protein (APP) and the generation of amyloid β (Aβ) peptides, Aβ42 and Aβ40, while also discussing which soluble or insoluble Aβ species (monomers, oligomers, protofibrils, or amyloid plaques) contribute to neuronal damage and the clinical manifestation of Alzheimer's disease.
Overlooked Neurological Features Present in Long COVID: Svetlana Blitshteyn, MD, FAAN
May 13th 2024The director of Dysautonomia Clinic talked about advocating for recognition and research into neurological symptoms that have long been overlooked in patients with Long COVID. [WATCH TIME: 3 minutes]
